We’ve recently updated our electronic health record and other systems to better support your care. We appreciate your patience and understanding as we work through this change and look forward to caring for you!
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with endometrial cancer that has come back (recurrent), does not respond to treatment (refractory), or has spread to other places in the body (metastatic). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
